Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Open Access
- 26 May 2021
- Vol. 13 (6), 989
- https://doi.org/10.3390/v13060989
Abstract
Objective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference (p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. In the ivermectin group, Ct increased from 15.13 ± 2.07 (day zero) to 30.14 ± 6.22 (day three; mean ± SD), compared to the control group, where the Ct values increased only from 14.20 ± 2.48 (day zero) to 18.96 ± 3.26 (day three; mean ± SD). Moreover, more subjects in the control group developed clinical symptoms. Three individuals (6%) required hospitalization, compared to the ivermectin group (0%). Conclusion: Ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2-positive subjects, effectively resulting in fewer symptoms, lower viral load and reduced hospital admissions. However, larger-scale trials are warranted for this conclusion to be further cemented.Keywords
This publication has 42 references indexed in Scilit:
- Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic DisordersMolecules, 2021
- COVID-19 in Pediatric Patients: A Focus on CHD PatientsFrontiers in Cardiovascular Medicine, 2020
- Hydroxychloroquine in COVID-19 Patients: Pros and ConsFrontiers in Pharmacology, 2020
- Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain InjuryThe Neuroscientist, 2020
- Dysregulation of Angiotensin Converting Enzyme 2 Expression and Function in Comorbid Disease Conditions Possibly Contributes to Coronavirus Infectious Disease 2019 Complication SeverityMolecular Pharmacology, 2020
- Characteristics of SARS-CoV-2 and COVID-19Nature Reviews Microbiology, 2020
- Have measures against COVID-19 helped to reduce dengue cases in Brazil?Travel Medicine and Infectious Disease, 2020
- Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK SignalingFrontiers in Pharmacology, 2020
- A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL proteaseTravel Medicine and Infectious Disease, 2020
- SARS-CoV-2 and Coronavirus Disease 2019: What We Know So FarPathogens, 2020